GleamWall
中文EN

PRME Prime Medicine, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1894562 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY55.3%
TTM net income YoY-2.7%
TTM EPS YoY18.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-4,498.1%
Net margin-4,342.4%
FCF margin-3,607.4%
EBITDA margin-4,340.0%

Returns

ROE-146.8%
ROA-62.8%
ROIC (approx.)-2,278.6%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets64.7%
Debt / equity0.00x
Current ratio4.84x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-12.1%
Payout ratio—
Capex / revenue97.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$4.21M——$838,000$1.23M$1.11M$1.45M$2.18M
R&D expense$34.12M$33.40M$34.10M$34.71M$43.99M$41.38M$40.56M$34.10M
SG&A expense$10.02M$11.04M$17.41M$14.74M$11.21M$13.12M$13.28M$12.30M
Operating income-$39.93M-$43.28M-$50.65M-$48.61M-$53.97M-$53.38M-$52.39M-$44.22M
Income tax—————$0$0$0
Net income-$39.04M-$42.11M-$49.12M-$46.08M-$50.58M-$52.59M-$51.89M-$42.28M
EBITDA-$38.17M-$41.50M-$48.80M-$46.73M-$52.09M-$51.51M-$50.69M-$42.51M
EPS (basic)-0.22-0.24-0.28—-0.32-0.41-0.40—
EPS (diluted)-0.22-0.24-0.28—-0.32-0.41-0.40—
Weighted avg. shares (diluted)177.86M177.22M177.10M—160.50M129.19M130.88M—
Balance sheet
Cash & equivalents$54.89M$47.45M$64.11M$63.03M$71.40M$53.80M$91.88M$196.54M
Short-term investments$6.27M$47.62M$71.39M$114.65M————
Current assets$63.69M$96.80M$137.89M$181.29M$231.41M$121.29M$163.76M$211.89M
PP&E, net$15.62M$17.08M$18.82M$20.57M$22.05M$23.83M$24.96M$24.40M
Total assets$213.85M$249.04M$294.73M$342.73M$385.01M$279.01M$328.16M$297.51M
Current liabilities$35.63M$31.69M$36.29M$37.45M$35.02M$34.11M$34.29M$37.96M
Total liabilities$205.42M$209.23M$218.03M$221.87M$223.19M$218.15M$221.24M$144.36M
Shareholders' equity$8.44M$39.81M$76.70M$120.87M$161.82M$60.86M$106.92M$153.15M
Shares outstanding181.39M180.74M180.62M180.51M180.31M134.49M131.16M131.16M
Cash flow statement
Operating cash flow-$36.68M-$41.05M-$42.71M-$37.26M-$35.04M-$41.41M-$48.86M$16.25M
Capital expenditure$298,000$46,000$214,000$290,000$247,000$1.57M$2.42M$1.79M
Free cash flow-$36.98M-$41.09M-$42.92M-$37.55M-$35.29M-$42.98M-$51.28M$14.45M
Investing cash flow$41.25M$24.03M$43.39M$28.33M-$92.12M$2.77M-$47.74M$48.25M
Financing cash flow$2.87M$361,000$393,000$562,000$144.75M$197,000$6.00M$1,000
Depreciation & amortization$1.76M$1.78M$1.86M$1.88M$1.88M$1.86M$1.70M$1.72M
Stock-based compensation$4.80M$4.87M$4.64M$4.51M$12.75M$6.33M$5.68M$5.94M

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.